Physician profile
John Gerard Devlin
NPI 1073728663
$30,563.74
in general payments reported to CMS, 2019-2025
95 companies · $9,168 in 2025
The $9,168 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,752 · 2020: $2,696 · 2021: $2,118 · 2022: $2,740 · 2023: $4,099 · 2024: $4,991 · 2025: $9,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Travel and Lodging: $2,530 · Education: $68.95 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,638.31 |
| Travel and Lodging | $2,530.16 |
| Education | $68.95 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $3,988.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,400.78 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,458.53 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $1,225.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,158.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,109.23 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $1,092.17 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $1,003.31 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $936.21 | 2019-2025 | Venclexta |
| Janssen Biotech, INC. | $893.18 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Astellas Pharma US INC | $873.74 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $803.58 | 2019-2023 | Imbruvica |
| Eisai INC. | $789.46 | 2019-2025 | |
| Incyte Corporation | $778.74 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Pharmaceuticals, INC | $706.60 | 2019-2025 | Xarelto, Balversa, Erleada |
Show all 95 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.